Tuesday, December 20, 2016

UPDATE 1-GSK's two-drug HIV therapy shines in two big studies

* Dolutegravir and rilpivirine work well in Phase III tests

(Adds further reaction, more detail on competition)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)